ArticleScientific reports2024

Class II HLA-DRB4 is a predictive biomarker for survival following immunotherapy in metastatic non-small cell lung cancer.

Cindy Y Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.